

mRNA-1273/tozinameran

S

Acute myocarditis: 5 case reports

A retrospective study conducted between 1 January 2021 and 25 May 2021 described one female and five male patients, aged 17–38 years, who developed acute myocarditis following administration of mRNA-1273 or tozinameran for immunisation against COVID-19.

Five patients received tozinameran [BNT162b2; 3 patients] and mRNA-1273 (2 patients) for immunisation against COVID-19 [*dosages and routes not stated*]. After 2–3 days from the second dose of vaccination, the patients developed chest pain. The patients also developed other symptoms including chills, headache, fever, chest discomfort, dyspnoea, body ache, fatigue, malaise, nausea, myalgias or lightheadedness. All patients were hospitalised. Cardiac MRI (performed 3–5 days after vaccination) and 12-lead ECG findings were consistent with acute myocarditis. Troponin-I level at peak was 1.02–14.65 ng/mL. B-type natriuretic peptide (BNP) was 38–75 pg/mL in two patients. Acute myocarditis was determined to be related to the vaccination [*time to reactions onset and outcomes not stated*].

Starekova J, et al. Myocarditis associated with mRNA COVID-19 vaccination. Radiology 301: 409, No. 2, Nov 2021. Available from: URL: <https://pubs.rsna.org/doi/pdf/10.1148/radiol.2021211430>

803624917